PURPOSE: Carbonyl reductase 1 (CBR1) reduces the anticancer anthracyclines doxorubicin and daunorubicin into the cardiotoxic metabolites doxorubicinol and daunorubicinol. We evaluated whether the cardioprotectant monoHER inhibits the activity of polymorphic CBR1. METHODS: We performed enzyme kinetic studies with monoHER, CBR1 (CBR1 V88 and CBR1 I88) and anthracycline substrates. We also characterized CBR1 inhibition by the related flavonoids triHER and quercetin. RESULTS: MonoHER inhibited the activity of CBR1 V88 and CBR1 I88 in a concentration-dependent manner. The IC(50) values of monoHER were lower for CBR1 I88 compared to CBR1 V88 for the substrates daunorubicin and doxorubicin (daunorubicin, IC(50)-CBR1 I88 = 164 microM vs. IC(50)-CBR1 V88 = 219 microM; doxorubicin, IC(50)-CBR1 I88 = 37 microM vs. IC(50)-CBR1 V88 = 59 microM; p < 0.001). Similarly, the flavonoids triHER and quercetin exhibited lower IC(50) values for CBR1 I88 compared to CBR1 V88 (p < 0.001). MonoHER acted as a competitive CBR1 inhibitor when using daunorubicin as a substrate Ki = 45 +/- 18 microM. MonoHER acted as an uncompetitive CBR1 inhibitor for the small quinone substrate menadione Ki = 33 +/- 17 microM. CONCLUSIONS: The cardioprotectant monoHER inhibits CBR1 activity. CBR1 V88I genotype status and the type of anthracycline substrate dictate the inhibition of CBR1 activity.
PURPOSE:Carbonyl reductase 1 (CBR1) reduces the anticancer anthracyclines doxorubicin and daunorubicin into the cardiotoxic metabolites doxorubicinol and daunorubicinol. We evaluated whether the cardioprotectant monoHER inhibits the activity of polymorphic CBR1. METHODS: We performed enzyme kinetic studies with monoHER, CBR1 (CBR1 V88 and CBR1 I88) and anthracycline substrates. We also characterized CBR1 inhibition by the related flavonoidstriHER and quercetin. RESULTS: MonoHER inhibited the activity of CBR1 V88 and CBR1 I88 in a concentration-dependent manner. The IC(50) values of monoHER were lower for CBR1 I88 compared to CBR1 V88 for the substrates daunorubicin and doxorubicin (daunorubicin, IC(50)-CBR1 I88 = 164 microM vs. IC(50)-CBR1 V88 = 219 microM; doxorubicin, IC(50)-CBR1 I88 = 37 microM vs. IC(50)-CBR1 V88 = 59 microM; p < 0.001). Similarly, the flavonoidstriHER and quercetin exhibited lower IC(50) values for CBR1 I88 compared to CBR1 V88 (p < 0.001). MonoHER acted as a competitive CBR1 inhibitor when using daunorubicin as a substrate Ki = 45 +/- 18 microM. MonoHER acted as an uncompetitive CBR1 inhibitor for the small quinone substrate menadione Ki = 33 +/- 17 microM. CONCLUSIONS: The cardioprotectant monoHER inhibits CBR1 activity. CBR1V88I genotype status and the type of anthracycline substrate dictate the inhibition of CBR1 activity.
Authors: Mohamed A I Abou El Hassan; Marc A Kedde; Ursula T H Zwiers; Aalt Bast; Wim J F van der Vijgh Journal: Cancer Chemother Pharmacol Date: 2003-03-22 Impact factor: 3.333
Authors: R D Olson; P S Mushlin; D E Brenner; S Fleischer; B J Cusack; B K Chang; R J Boucek Journal: Proc Natl Acad Sci U S A Date: 1988-05 Impact factor: 11.205
Authors: A M E Bruynzeel; H W M Niessen; J G F Bronzwaer; J J M van der Hoeven; J Berkhof; A Bast; W J F van der Vijgh; C J van Groeningen Journal: Br J Cancer Date: 2007-10-16 Impact factor: 7.640
Authors: Lars P Jordheim; Vincent Ribrag; Hervé Ghesquieres; Sophie Pallardy; Richard Delarue; Hervé Tilly; Corinne Haioun; Fabrice Jardin; Delphine Demangel; Gilles A Salles; Charles Dumontet Journal: Haematologica Date: 2015-01-30 Impact factor: 9.941
Authors: Vanessa Gonzalez-Covarrubias; Jianping Zhang; James L Kalabus; Mary V Relling; Javier G Blanco Journal: Drug Metab Dispos Date: 2008-11-20 Impact factor: 3.922
Authors: Vladimír Kubíček; Lenka Skálová; Adam Skarka; Věra Králová; Jana Holubová; Jana Štěpánková; Zdeněk Šubrt; Barbora Szotáková Journal: Front Pharmacol Date: 2019-05-28 Impact factor: 5.810